Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib nivolumab plus ASP-1929 photoimmunotherapy in advanced or recurrent gastric or esophageal cancer
jRCT2080224884Phase 1Completed
- Sponsor
- Rakuten Medical, Inc.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and cetuximab sarotalocan sodium in gastric cancer (GC) and esophageal cancer, sponsored by Rakuten Medical, Inc. Started Sep 2019; status: completed.
02
Drugs
nivolumabcetuximab sarotalocan sodium
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on jRCT2080224884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224884.